We are live on
!
Find out more
DY
Dowling & Yahnke Portfolio holdings
AUM
$2.15B
Turnover
6.98%
1-Year Est. Return
10.82%
This Fund
S&P 500
This Quarter
Est. Return
+6.39%
1 Year Est. Return
-10.82%
3 Year Est. Return
+34.82%
5 Year Est. Return
+71.23%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
+$121M
(+12%)
Cap. Flow
+$60.5M
Cap. Flow
% of AUM
5.47%
Top 10 Holdings %
Top 10 Hldgs %
22.97%
Holding
307
New
21
Increased
95
Reduced
149
Closed
16
Avg Time Held
3.5
years
Top 10 Avg Time Held
3
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Emerging Markets Government Bond ETF
VWOB
|
+$38.6M |
| 2 |
Vanguard Global ex-US Real Estate ETF
VNQI
|
+$12.4M |
| 3 |
Global X S&P 500 Catholic Values ETF
CATH
|
+$3.35M |
| 4 |
Vanguard Total International Bond ETF
BNDX
|
+$2.4M |
| 5 |
Vanguard Real Estate ETF
VNQ
|
+$2.01M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Aerospace
GE
|
+$1.53M |
| 2 |
The Marzetti Company
MZTI
|
+$787K |
| 3 |
ExxonMobil
XOM
|
+$601K |
| 4 |
AGN
Allergan Inc
AGN
|
+$428K |
| 5 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$346K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.68% |
| 2 | Healthcare | 12.86% |
| 3 | Financials | 12.1% |
| 4 | Technology | 12.09% |
| 5 | Consumer Staples | 10.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
276
Bio-Rad Laboratories Class A
BIO
$9.75B
| $221K | 0.02% |
927
-83
| -8% | -$20.1K |
2017 Q1
3 quarters
|
|
277
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$22.2B
| $221K | 0.02% |
4,486
-722
| -14% | -$34K |
2017 Q2
2 quarters
|
|
278
Franklin Templeton
BEN
$15.9B
| $218K | 0.02% |
5,028
-90
| -2% | -$3.9K |
2016 Q3
5 quarters
|
|
279
Edwards Lifesciences
EW
$50.8B
| $218K | 0.02% |
+5,808
| New | +$213K |
2017 Q4
0 quarters
|
|
|
ESL
280
DELISTED
Esterline Technologies
ESL
| $217K | 0.02% |
+2,900
| New | +$238K |
2017 Q4
0 quarters
|
|
281
Novartis
NVS
$286B
| $213K | 0.02% |
2,834
| – | – |
2017 Q1
3 quarters
|
|
282
DoubleLine Income Solutions Fund
DSL
$1.12B
| – | – |
0
| – | – |
2017 Q4
0 quarters
|
|
283
APA Corp
APA
$16.5B
| $210K | 0.02% |
4,969
-985
| -17% | -$41.5K |
2013 Q2
18 quarters
|
|
284
ResMed
RMD
$34.1B
| $208K | 0.02% |
+2,460
| New | +$203K |
2017 Q4
0 quarters
|
|
285
abrdn Physical Gold Shares ETF
SGOL
$6.97B
| $208K | 0.02% |
16,500
| – | – |
2017 Q3
1 quarter
|
|
|
AGN
286
DELISTED
Allergan plc
AGN
| $205K | 0.02% |
+1,253
| New | +$225K |
2017 Q4
0 quarters
|
|
287
Charter Communications
CHTR
$12.6B
| $203K | 0.02% |
605
-14
| -2% | -$4.76K |
2017 Q1
3 quarters
|
|
|
DYSL
288
DELISTED
Dynasil Corporation of America
DYSL
| $179K | 0.02% |
151,301
+5,000
| +3% | +$6.57K |
2013 Q2
18 quarters
|
|
289
DELISTED
Forte Biosciences
FBRX
| $169K | 0.02% |
+44
| New | +$176K |
2017 Q4
0 quarters
|
|
290
Actinium Pharmaceuticals
ATNM
$33.3M
| $15K | ﹤0.01% |
762
| – | – |
2015 Q4
8 quarters
|
|
291
DELISTED
Regulus Therapeutics
RGLS
| $12K | ﹤0.01% |
96
| – | – |
2017 Q1
3 quarters
|
|
292
iShares MSCI Global Min Vol Factor ETF
ACWV
$3.4B
| – | – |
-2,976
| Closed | -$242K | – |
|
293
Adient
ADNT
$1.4B
| – | – |
-2,710
| Closed | -$228K | – |
|
294
Immunic
IMUX
$96.9M
| – | – |
-125
| Closed | -$252K | – |
|
295
Tandem Diabetes Care
TNDM
$1.15B
| – | – |
-1,757
| Closed | -$13K | – |
|
296
Worthington Enterprises
WOR
$3.14B
| – | – |
-8,360
| Closed | -$237K | – |
|
297
DELISTED
Windtree Therapeutics Inc
WINT
| – | – |
-20,003
| Closed | -$4K | – |
|
|
LQMT
298
DELISTED
LIQUIDMETAL TECHNOLOGIES INC
LQMT
| – | – |
-213,000
| Closed | -$83K | – |
|
|
AGN
299
DELISTED
Allergan Inc
AGN
| – | – |
-2,086
| Closed | -$428K | – |
|
Similar funds
AC
APA
IC
SCA
ACM
W
Dowling & Yahnke's Q4 2017 Portfolio in Review
As of Q4 2017, Dowling & Yahnke held 307 positions worth $1.11B, up 12% from $985M the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Dowling & Yahnke deployed $60.5M of net new capital in Q4 2017, opening 21 new positions and adding to 95 existing holdings. Its largest new stake was Vanguard Emerging Markets Government Bond ETF: 479,412 shares worth $38.5M.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was GE Aerospace, an estimated $1.53M trimmed.
- Dowling & Yahnke's largest Q4 2017 buy was Vanguard Emerging Markets Government Bond ETF: 479,412 shares worth $38.5M.
- Dowling & Yahnke added most to DexCom in Q4 2017, an estimated $1.82M increase.
- Dowling & Yahnke's biggest Q4 2017 reduction was GE Aerospace, cutting an estimated $1.53M.
- Dowling & Yahnke fully exited Allergan Inc in Q4 2017, selling an estimated $428K.
- Dowling & Yahnke's ten largest holdings make up 23% of its $1.11B portfolio in Q4 2017.
- Dowling & Yahnke opened 21 new positions and closed 16 in Q4 2017.
- Dowling & Yahnke's portfolio value rose 12% quarter-over-quarter to $1.11B.
Based on Dowling & Yahnke's 13F filing for Q4 2017, filed 2 Feb 2018.